ReferenceID 628
The spinal microglial IL-10/β-endorphin pathway accounts for cinobufagin-induced mechanical antiallodynia in bone cancer pain following activation of α7-nicotinic acetylcholine receptors
J Neuroinflammation
BACKGROUND: Cinobufagin is the major bufadienolide of Bufonis venenum (Chansu), which has been traditionally used for the treatment of chronic pain especially cancer pain. The current study aimed to evaluate its antinoci
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 628
- Evidence Id
- 17218
- Core Evidence Id
- 17218
- Source Reference Id
- 1248
- Herb2 Reference Id
- HBREF002045
- Subject Paper Key
- HERB000650_32113469
- Pubmed Id
- 32113469
- Doi
- 10.1186/s12974-019-1616-z
- Paper Title
- The spinal microglial IL-10/β-endorphin pathway accounts for cinobufagin-induced mechanical antiallodynia in bone cancer pain following activation of α7-nicotinic acetylcholine receptors
- Paper Abstract
- BACKGROUND: Cinobufagin is the major bufadienolide of Bufonis venenum (Chansu), which has been traditionally used for the treatment of chronic pain especially cancer pain. The current study aimed to evaluate its antinociceptive effects in bone cancer pain and explore the underlying mechanisms. METHODS: Rat bone cancer model was used in this study. The withdrawal threshold evoked by stimulation of the hindpaw was determined using a 2290 CE electrical von Frey hair. The beta-endorphin and IL-10 levels were measured in the spinal cord and cultured primary microglia, astrocytes, and neurons. RESULTS: Cinobufagin, given intrathecally, dose-dependently attenuated mechanical allodynia in bone cancer pain rats, with the projected Emax of 90% MPE and ED50 of 6.4 mug. Intrathecal cinobufagin also stimulated the gene and protein expression of IL-10 and beta-endorphin (but not dynorphin A) in the spinal cords of bone cancer pain rats. In addition, treatment with cinobufagin in cultured primary spinal microglia but not astrocytes or neurons stimulated the mRNA and protein expression of IL-10 and beta-endorphin, which was prevented by the pretreatment with the IL-10 antibody but not beta-endorphin antiserum. Furthermore, spinal cinobufagin-induced mechanical antiallodynia was inhibited by the pretreatment with intrathecal injection of the microglial inhibitor minocycline, IL-10 antibody, beta-endorphin antiserum and specific mu-opioid receptor antagonist CTAP. Lastly, cinobufagin- and the specific alpha-7 nicotinic acetylcholine receptor (alpha7-nAChR) agonist PHA-543613-induced microglial gene expression of IL-10/beta-endorphin and mechanical antiallodynia in bone cancer pain were blocked by the pretreatment with the specific alpha7-nAChR antagonist methyllycaconitine. CONCLUSIONS: Our results illustrate that cinobufagin produces mechanical antiallodynia in bone cancer pain through spinal microglial expression of IL-10 and subsequent beta-endorphin following activation of alpha7-nAChRs. Our results also highlight the broad significance of the recently uncovered spinal microglial IL-10/beta-endorphin pathway in antinociception.
- Journal
- J Neuroinflammation
- Publish Year
- 2020
- Experiment Subject
- rat; cultured primary microglia; cultured primary spinal microglia
- Experiment Type
- Animal Experiment
- Phenotype Related
- Chronic Pain; Bone Cancer; Cancer Pain
- Paper Title Cn
- Paper Title En
- The spinal microglial IL-10/β-endorphin pathway accounts for cinobufagin-induced mechanical antiallodynia in bone cancer pain following activation of α7-nicotinic acetylcholine receptors
- Bilingual Status
- semi_complete